JPMorgan Raises Johnson & Johnson Price Target

Analysts see upside potential in pharmaceutical giant's stock

Mar. 5, 2026 at 9:23pm

Got story updates? Submit your updates here. ›

JPMorgan Chase & Co. analysts have raised their price target on Johnson & Johnson (NYSE:JNJ) stock from $225 to $250, maintaining a "neutral" rating. The analysts cited the pharmaceutical company's strong performance and growth potential as reasons for the increased price target.

Why it matters

Johnson & Johnson is one of the world's largest and most diversified healthcare companies, with a strong presence in pharmaceuticals, medical devices, and consumer products. An increase in the company's stock price target by a major investment bank signals confidence in the company's future growth and profitability.

The details

In a research note, JPMorgan analysts cited Johnson & Johnson's robust product pipeline and market position as factors contributing to the increased price target. The analysts believe the company's pharmaceutical business, which accounts for a significant portion of its revenue, will continue to drive growth.

  • The new price target was issued on Thursday, March 5, 2026.

The players

JPMorgan Chase & Co.

A multinational investment bank and financial services company headquartered in New York City.

Johnson & Johnson

A multinational pharmaceutical and consumer goods company headquartered in New Brunswick, New Jersey.

Got photos? Submit your photos here. ›

The takeaway

The increased price target from JPMorgan Chase & Co. suggests that Wall Street analysts see continued growth potential in Johnson & Johnson's diversified healthcare business, despite the stock already trading near all-time highs.